Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 29

Publication Record


Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy.
Van Driest SL, McGregor TL, Velez Edwards DR, Saville BR, Kitchner TE, Hebbring SJ, Brilliant M, Jouni H, Kullo IJ, Creech CB, Kannankeril PJ, Vear SI, Brothers KB, Bowton EA, Shaffer CM, Patel N, Delaney JT, Bradford Y, Wilson S, Olson LM, Crawford DC, Potts AL, Ho RH, Roden DM, Denny JC
(2015) PLoS One 10: e0127791
MeSH Terms: Adult, Aged, Chromosomes, Human, Chromosomes, Human, Pair 6, Connexin 43, Creatinine, Female, GTPase-Activating Proteins, Genome-Wide Association Study, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Vancomycin
Show Abstract · Added February 22, 2016
Vancomycin, a commonly used antibiotic, can be nephrotoxic. Known risk factors such as age, creatinine clearance, vancomycin dose / dosing interval, and concurrent nephrotoxic medications fail to accurately predict nephrotoxicity. To identify potential genomic risk factors, we performed a genome-wide association study (GWAS) of serum creatinine levels while on vancomycin in 489 European American individuals and validated findings in three independent cohorts totaling 439 European American individuals. In primary analyses, the chromosome 6q22.31 locus was associated with increased serum creatinine levels while on vancomycin therapy (most significant variant rs2789047, risk allele A, β = -0.06, p = 1.1 x 10(-7)). SNPs in this region had consistent directions of effect in the validation cohorts, with a meta-p of 1.1 x 10(-7). Variation in this region on chromosome 6, which includes the genes TBC1D32/C6orf170 and GJA1 (encoding connexin43), may modulate risk of vancomycin-induced kidney injury.
0 Communities
5 Members
0 Resources
15 MeSH Terms
Validation of two vancomycin nomograms in patients 10 years of age and older.
Gillon JE, Cassat JE, Di Pentima MC
(2014) J Clin Pharmacol 54: 35-8
MeSH Terms: Adolescent, Adult, Anti-Bacterial Agents, Body Weight, Child, Creatine, Female, Guidelines as Topic, Humans, Male, Reproducibility of Results, Vancomycin, Young Adult
Added January 20, 2015
0 Communities
1 Members
0 Resources
13 MeSH Terms
Incidence of catheter-related bloodstream infections in neonates following removal of peripherally inserted central venous catheters.
Casner M, Hoesli SJ, Slaughter JC, Hill M, Weitkamp JH
(2014) Pediatr Crit Care Med 15: 42-8
MeSH Terms: Anti-Bacterial Agents, Apnea, Birth Weight, Bradycardia, Catheter-Related Infections, Catheterization, Peripheral, Catheters, Indwelling, Central Venous Catheters, Device Removal, Female, Gestational Age, Humans, Incidence, Infant, Newborn, Infant, Very Low Birth Weight, Male, Prevalence, Sepsis, Time Factors, Vancomycin
Show Abstract · Added February 27, 2014
OBJECTIVES - Catheter-associated bloodstream infections are a significant source of morbidity and healthcare cost in the neonatal ICU. Previous studies examining the prevalence of bloodstream infections after removal of peripherally inserted central venous catheters in neonates are equivocal.
DESIGN - A retrospective cohort study.
PATIENTS - All infants with peripherally inserted central venous catheters treated at the Vanderbilt neonatal ICU between 2007 and 2009.
MEASUREMENTS AND MAIN RESULTS - We evaluated the following outcomes: 1) bloodstream infections, 2) culture-negative sepsis, 3) number of sepsis evaluations, and 4) number of significant apnea/bradycardia events comparing odds ratios between 72 hours before and 72 hours after peripherally inserted central venous catheter removal. We analyzed a total of 1,002 peripherally inserted central venous catheters in 856 individual infants with a median (interquartile range) gestational age of 31 weeks (28-37 wk) and a median birth weight of 1,469 g (960-2,690 g). Comparing 72 hours before with 72 hours after peripherally inserted central venous catheter removal did not show a difference in the prevalence of bloodstream infections (9 vs 3, p = 0.08), prevalence of culture-negative sepsis (37 vs 40, p = 0.73), number of sepsis evaluations (p = 0.42), or number of apnea/bradycardia events (p = 0.32). However, in peripherally inserted central venous catheter not used for delivery of antibiotics, there was a 3.83-fold increase in odds for culture-negative sepsis following peripherally inserted central venous catheter removal (95% confidence interval, 1.48-10.5; p = 0.001). For infants less than 1,500 g birth weight (very low birth weight), odds for culture-negative sepsis increased to 6.3-fold following removal of peripherally inserted central venous catheters not used for antibiotic delivery (95% confidence interval, 1.78-26.86; p < 0.01).
CONCLUSIONS - Although these data do not support the routine use of antibiotics for sepsis prophylaxis prior to peripherally inserted central venous catheter removal, they suggests that very low birth weight infants not recently exposed to antibiotics are at increased odds for associated adverse events following discontinuation of their peripherally inserted central venous catheter.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.
Chan KE, Warren HS, Thadhani RI, Steele DJ, Hymes JL, Maddux FW, Hakim RM
(2012) J Am Soc Nephrol 23: 1551-9
MeSH Terms: Anti-Bacterial Agents, Bacteremia, Cefazolin, Comorbidity, Female, Humans, Kidney Failure, Chronic, Longitudinal Studies, Male, Methicillin-Resistant Staphylococcus aureus, Middle Aged, Outpatients, Prevalence, Renal Dialysis, Retrospective Studies, Risk Factors, Staphylococcal Infections, Staphylococcus aureus, Treatment Outcome, United States, Vancomycin
Show Abstract · Added May 20, 2014
Staphylococcus bacteremia is a common and life-threatening medical emergency, but it is treatable with appropriate antibiotic therapy. To identify opportunities that may reduce morbidity and mortality associated with S. aureus, we analyzed data from 293,094 chronic hemodialysis outpatients to characterize practices of antibiotic selection. In the study population, the overall rate of bacteremia was 15.4 per 100 outpatient-years; the incidence rate for methicillin-sensitive (MSSA) was 2.1 per 100 outpatient-years, and the incidence rate for methicillin-resistant (MRSA) S. aureus was 1.9 per 100 outpatient-years. One week after the collection of the index blood culture, 56.1% of outpatients with MSSA bacteremia were receiving vancomycin, and 16.7% of outpatients with MSSA were receiving cefazolin. Among MSSA-bacteremic patients who did not die or get hospitalized 1 week after blood culture collection, use of cefazolin was associated with a 38% lower risk for hospitalization or death compared with vancomycin (adjusted HR=0.62, 95% CI=0.46-0.84). In conclusion, vancomycin is commonly used to treat MSSA bacteremia in outpatients receiving chronic dialysis, but there may be more risk of treatment failure than observed among those individuals who receive a β-lactam antibiotic such as cefazolin.
0 Communities
1 Members
0 Resources
21 MeSH Terms
Dual-purpose bone grafts improve healing and reduce infection.
Guelcher SA, Brown KV, Li B, Guda T, Lee BH, Wenke JC
(2011) J Orthop Trauma 25: 477-82
MeSH Terms: Animals, Anti-Bacterial Agents, Bone Morphogenetic Protein 2, Bone Transplantation, Combined Modality Therapy, Delayed-Action Preparations, Femoral Fractures, Fracture Healing, Guided Tissue Regeneration, Osteitis, Rats, Tissue Scaffolds, Treatment Outcome, Vancomycin
Show Abstract · Added February 23, 2016
OBJECTIVE - To determine if a dual-purpose bone graft can regenerate bone and reduce infection in highly contaminated bone critical size defects in rats.
METHODS - Biodegradable polyurethane (PUR) scaffolds were loaded with recombinant human bone morphogenetic protein-2 (BMP-2) and vancomycin (Vanc). The release kinetics of the BMP-2 were tuned to take advantage of its mechanism of action (ie, an initial burst to recruit cells and sustained release to induce differentiation of the migrating cells). The Vanc release kinetics were designed to protect the graft from contamination until it is vascularized by having a burst for a week and remaining well over the minimum inhibitory concentration for Staphylococcus aureus for 2 months. The bone regeneration and infection reduction capability of these dual-purpose grafts (PUR+Vanc+BMP-2) were compared with collagen sponges loaded with BMP-2 (collagen+BMP-2) and PUR+BMP-2 in infected critical size rat femoral segmental defects.
RESULTS - The dual-delivery approach resulted in substantially more new bone formation and a modest improvement in infection than PUR+BMP-2 and collagen+BMP-2 treatments.
CONCLUSIONS - The PUR bone graft is injectable, provides a more sustained release of BMP-2 than the collagen sponge, and can release antibiotics for more than 8 weeks. Thus, the dual-delivery approach may improve patient outcomes of open fractures by protecting the osteoinductive graft from colonization until vascularization occurs. In addition, the more optimal release kinetics of BMP-2 may reduce nonunions and the amount of growth factor required.
1 Communities
1 Members
0 Resources
14 MeSH Terms
Computational design of an endo-1,4-beta-xylanase ligand binding site.
Morin A, Kaufmann KW, Fortenberry C, Harp JM, Mizoue LS, Meiler J
(2011) Protein Eng Des Sel 24: 503-16
MeSH Terms: Actinomycetales, Binding Sites, Computational Biology, Computer Simulation, Crystallography, Endo-1,4-beta Xylanases, Molecular Dynamics Simulation, Monte Carlo Method, Protein Engineering, Protein Structure, Tertiary, Software, Vancomycin
Show Abstract · Added January 24, 2015
The field of computational protein design has experienced important recent success. However, the de novo computational design of high-affinity protein-ligand interfaces is still largely an open challenge. Using the Rosetta program, we attempted the in silico design of a high-affinity protein interface to a small peptide ligand. We chose the thermophilic endo-1,4-β-xylanase from Nonomuraea flexuosa as the protein scaffold on which to perform our designs. Over the course of the study, 12 proteins derived from this scaffold were produced and assayed for binding to the target ligand. Unfortunately, none of the designed proteins displayed evidence of high-affinity binding. Structural characterization of four designed proteins revealed that although the predicted structure of the protein model was highly accurate, this structural accuracy did not translate into accurate prediction of binding affinity. Crystallographic analyses indicate that the lack of binding affinity is possibly due to unaccounted for protein dynamics in the 'thumb' region of our design scaffold intrinsic to the family 11 β-xylanase fold. Further computational analysis revealed two specific, single amino acid substitutions responsible for an observed change in backbone conformation, and decreased dynamic stability of the catalytic cleft. These findings offer new insight into the dynamic and structural determinants of the β-xylanase proteins.
1 Communities
2 Members
0 Resources
12 MeSH Terms
Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis.
Olson PD, Kuechenmeister LJ, Anderson KL, Daily S, Beenken KE, Roux CM, Reniere ML, Lewis TL, Weiss WJ, Pulse M, Nguyen P, Simecka JW, Morrison JM, Sayood K, Asojo OA, Smeltzer MS, Skaar EP, Dunman PM
(2011) PLoS Pathog 7: e1001287
MeSH Terms: Animals, Anti-Infective Agents, Female, Hep G2 Cells, Humans, Mice, Models, Biological, RNA Processing, Post-Transcriptional, RNA, Messenger, Ribonuclease P, Small Molecule Libraries, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Virulence
Show Abstract · Added February 11, 2016
Methicillin-resistant Staphylococcus aureus is estimated to cause more U.S. deaths annually than HIV/AIDS. The emergence of hypervirulent and multidrug-resistant strains has further amplified public health concern and accentuated the need for new classes of antibiotics. RNA degradation is a required cellular process that could be exploited for novel antimicrobial drug development. However, such discovery efforts have been hindered because components of the Gram-positive RNA turnover machinery are incompletely defined. In the current study we found that the essential S. aureus protein, RnpA, catalyzes rRNA and mRNA digestion in vitro. Exploiting this activity, high through-put and secondary screening assays identified a small molecule inhibitor of RnpA-mediated in vitro RNA degradation. This agent was shown to limit cellular mRNA degradation and exhibited antimicrobial activity against predominant methicillin-resistant S. aureus (MRSA) lineages circulating throughout the U.S., vancomycin intermediate susceptible S. aureus (VISA), vancomycin resistant S. aureus (VRSA) and other Gram-positive bacterial pathogens with high RnpA amino acid conservation. We also found that this RnpA-inhibitor ameliorates disease in a systemic mouse infection model and has antimicrobial activity against biofilm-associated S. aureus. Taken together, these findings indicate that RnpA, either alone, as a component of the RNase P holoenzyme, and/or as a member of a more elaborate complex, may play a role in S. aureus RNA degradation and provide proof of principle for RNA catabolism-based antimicrobial therapy.
0 Communities
1 Members
0 Resources
15 MeSH Terms
Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model.
Li B, Brown KV, Wenke JC, Guelcher SA
(2010) J Control Release 145: 221-30
MeSH Terms: Animals, Anti-Bacterial Agents, Delayed-Action Preparations, Femur, Polyurethanes, Rats, Rats, Sprague-Dawley, Vancomycin, Wound Infection
Show Abstract · Added February 23, 2016
Infection is a common complication in open fractures that compromises the healing of bone and can result in loss of limb or life. Currently, the clinical standard of care for treating contaminated open fractures comprises a staged approach, wherein the wound is first treated with non-biodegradable antibiotic-laden poly(methyl methacrylate) (PMMA) beads to control the infection followed by bone grafting. Considering that tissue regeneration is associated with new blood vessel formation, which takes up to 6 weeks in segmental defects, a biodegradable bone graft with sustained release of an antibiotic is desired to prevent the implant from becoming infected, thus allowing the processes of both vascularization and new bone formation to occur unimpeded. In the present study, we utilized biodegradable porous polyurethane (PUR) scaffolds as the delivery vehicle for vancomycin. Hydrophobic vancomycin free base (V-FB) was obtained by precipitating the hydrophilic vancomycin hydrochloride (V-HCl) at pH 8. The decreased solubility of V-FB resulted in an extended vancomycin release profile in vitro, as evidenced by the fact that active vancomycin was released for up to 8 weeks at concentrations well above both the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). Using PUR prepared from lysine triisocyanate (LTI) (PUR(LTI)), the extended in vitro release profile observed for V-FB translated to improved infection control in vivo compared to V-HCl in a contaminated critical-sized fat femoral segmental defect. The performance of PUR(LTI)/V-FB was comparable to PMMA/V-HCl beads in vivo. However, compared with PMMA, PUR is a biodegradable system which does not require the extra surgical removal step in clinical use. These results suggest that PUR scaffolds incorporating V-FB could be a potential clinical therapy for treatment of infected bone defects.
Copyright (c) 2010 Elsevier B.V. All rights reserved.
1 Communities
1 Members
0 Resources
9 MeSH Terms
Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?
Jimenez-Truque N, Thomsen I, Saye E, Creech CB
(2010) Pediatr Infect Dis J 29: 368-70
MeSH Terms: Anti-Bacterial Agents, Child, Community-Acquired Infections, Humans, Methicillin-Resistant Staphylococcus aureus, Microbial Sensitivity Tests, Staphylococcal Infections, Vancomycin
Show Abstract · Added February 3, 2014
Methicillin-resistant Staphylococcus aureus isolates with vancomycin minimal inhibitory concentrations (MICs) >or=1.5 microg/mL have been associated with poorer clinical outcomes and treatment failures in adults. We evaluated vancomycin MICs in 71 invasive pediatric community-acquired MRSA isolates from 2004 to 2008, using the E-test micromethod and the E-test macro-method. The modal MIC by micromethod was 1.5 microg/mL, and median vancomycin MICs did not increase over time.
0 Communities
1 Members
0 Resources
8 MeSH Terms
Risk factors for treatment failure in patients receiving vancomycin for hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia.
Aston JL, Dortch MJ, Dossett LA, Creech CB, May AK
(2010) Surg Infect (Larchmt) 11: 21-8
MeSH Terms: Aged, Animals, Anti-Bacterial Agents, Critical Care, Cross Infection, Drug Utilization, Female, Humans, Male, Methicillin-Resistant Staphylococcus aureus, Middle Aged, Pneumonia, Staphylococcal, Retrospective Studies, Risk Factors, Treatment Failure, Vancomycin
Show Abstract · Added February 3, 2014
BACKGROUND - The rate of vancomycin failure in patients with hospital-acquired pneumonia (HAP) caused by methicillin-resistant Staphylococcus aureus (MRSA) has exceeded 40% in several studies. This observation was attributed initially to the lack of weight-based dosing and targeting of lower trough concentrations. However, a subsequent study demonstrated no additional benefit in patients who achieved trough vancomycin concentrations >15 mg/L compared with patients with concentrations between 5 and 15 mg/L. We sought to identify contributors to vancomycin failure in patients with MRSA HAP.
METHODS - This was a retrospective study of patients in a surgical intensive care unit with MRSA HAP who received vancomycin between January 1, 2005, and July 31, 2007. Clinical outcomes, microbiological data, prior antibiotic exposure, ventilator days, co-morbidities, and demographics were compared in patients with clinical success and those with treatment failure. Their characteristics were compared using a two-sided Fisher exact test or Mann-Whitney U test, as appropriate for nominal or continuous data.
RESULTS - More patients in the treatment failure group had received one or more doses of vancomycin within 90 days leading up to MRSA HAP (84% vs. 47%; p = 0.04). In addition, the duration of prior vancomycin exposure was significantly longer among patients in the treatment failure group (6 vs. 0 days; p < 0.05). There were no statistically significant differences in the percentages of patients who achieved a vancomycin trough concentrations > or =15 mg/dL within the first 48 h (28% vs. 17%; p = 0.69), 72 h (44% vs. 39%; p = 1.0), or 96 h (56% vs. 44%; p = 0.74) after starting treatment. Patients in the failure group had a significantly higher overall mortality rate (32% vs. 0; p = 0.02).
CONCLUSIONS - These data suggest that patients who have recent exposure to vancomycin are at high risk for vancomycin failure and may benefit from an appropriate alternative when a diagnosis of MRSA HAP is made.
0 Communities
1 Members
0 Resources
16 MeSH Terms